Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590198146> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2590198146 endingPage "133" @default.
- W2590198146 startingPage "133" @default.
- W2590198146 abstract "133 Background: We performed multicenter retrospective study to evaluate the activity and the safety of a docetaxel as the third-line chemotherapy in advanced gastric cancer (AGC) patients who had undergone oxaliplatin (FOLFOX) and irinotecan (FOLFIRI)-based chemotherapy regimens. Methods: Thirty-eight patients with AGC previously treated were eligible for this study. Patients received docetaxel 30 mg/m 2 +/- cisplatin 30 mg/m 2 IV on day 1, 8 or docetaxel 60 mg/m 2 +/- cisplatin 60 mg/m 2 IV on day 1 every 3 weeks until disease progression, and responses were assessed after every two cycles according to RECIST criteria and toxicity was evaluated by NCI-CTC. Results: Thirty-two out of 38 patients were evaluable for response. A total of 95.1 cycles of chemotherapy (median 2, range 0.5–7) were administered. Relative dose intensities of docetaxel and cisplatin were 93.4% and 87.8%, respectively. The overall response rate was 15.6% and the disease control rate was 50%. With a median follow-up duration of 3.1 months (range 0.3-14.3 months), 36 patients had disease progression, and 34 patients had died at the time of analysis. The median progression-free survival was 1.8 months (95% CI, 1.3–2.3 months). The median overall survival was 3.1 months (95% CI, 2.3–3.9 months). Grade 3 or 4 hematologic toxicities included neutropenia in thirteen patients (38.3%), febrile neutropenia in four patients (11.7%). and thrombocytopenia in one patient (2.9%). Other grade 3 or 4 toxicities included neuropathy in three patients (8.8%) and mucositis in two patients (5.9%). There were three treatment-related deaths (8.8%) caused by infection associated with neutropenia. Conclusions: Salvage docetaxel chemotherapy in AGC patients failed in oxaliplatin and irinotecan-based treatment is not recommend routinely. However, selected patients with good performance status and sufficient albumin levels may have derived some survival benefits from salvage chemotherapy. No significant financial relationships to disclose." @default.
- W2590198146 created "2017-03-03" @default.
- W2590198146 creator A5011928803 @default.
- W2590198146 creator A5036700956 @default.
- W2590198146 creator A5060913021 @default.
- W2590198146 creator A5066871980 @default.
- W2590198146 creator A5084786302 @default.
- W2590198146 creator A5086393090 @default.
- W2590198146 date "2011-02-01" @default.
- W2590198146 modified "2023-09-26" @default.
- W2590198146 title "Treatment outcome and safety of docetaxel as the third-line chemotherapy in advanced gastric cancer after progression or after failure of FOLFOX and FOLFIRI-based sequential chemotherapy." @default.
- W2590198146 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.133" @default.
- W2590198146 hasPublicationYear "2011" @default.
- W2590198146 type Work @default.
- W2590198146 sameAs 2590198146 @default.
- W2590198146 citedByCount "0" @default.
- W2590198146 crossrefType "journal-article" @default.
- W2590198146 hasAuthorship W2590198146A5011928803 @default.
- W2590198146 hasAuthorship W2590198146A5036700956 @default.
- W2590198146 hasAuthorship W2590198146A5060913021 @default.
- W2590198146 hasAuthorship W2590198146A5066871980 @default.
- W2590198146 hasAuthorship W2590198146A5084786302 @default.
- W2590198146 hasAuthorship W2590198146A5086393090 @default.
- W2590198146 hasConcept C121608353 @default.
- W2590198146 hasConcept C126322002 @default.
- W2590198146 hasConcept C141071460 @default.
- W2590198146 hasConcept C143998085 @default.
- W2590198146 hasConcept C2776694085 @default.
- W2590198146 hasConcept C2776705615 @default.
- W2590198146 hasConcept C2777063308 @default.
- W2590198146 hasConcept C2778239845 @default.
- W2590198146 hasConcept C2778260052 @default.
- W2590198146 hasConcept C2778850193 @default.
- W2590198146 hasConcept C2780259306 @default.
- W2590198146 hasConcept C2780962732 @default.
- W2590198146 hasConcept C2781190966 @default.
- W2590198146 hasConcept C526805850 @default.
- W2590198146 hasConcept C71924100 @default.
- W2590198146 hasConcept C90924648 @default.
- W2590198146 hasConceptScore W2590198146C121608353 @default.
- W2590198146 hasConceptScore W2590198146C126322002 @default.
- W2590198146 hasConceptScore W2590198146C141071460 @default.
- W2590198146 hasConceptScore W2590198146C143998085 @default.
- W2590198146 hasConceptScore W2590198146C2776694085 @default.
- W2590198146 hasConceptScore W2590198146C2776705615 @default.
- W2590198146 hasConceptScore W2590198146C2777063308 @default.
- W2590198146 hasConceptScore W2590198146C2778239845 @default.
- W2590198146 hasConceptScore W2590198146C2778260052 @default.
- W2590198146 hasConceptScore W2590198146C2778850193 @default.
- W2590198146 hasConceptScore W2590198146C2780259306 @default.
- W2590198146 hasConceptScore W2590198146C2780962732 @default.
- W2590198146 hasConceptScore W2590198146C2781190966 @default.
- W2590198146 hasConceptScore W2590198146C526805850 @default.
- W2590198146 hasConceptScore W2590198146C71924100 @default.
- W2590198146 hasConceptScore W2590198146C90924648 @default.
- W2590198146 hasIssue "4_suppl" @default.
- W2590198146 hasLocation W25901981461 @default.
- W2590198146 hasOpenAccess W2590198146 @default.
- W2590198146 hasPrimaryLocation W25901981461 @default.
- W2590198146 hasRelatedWork W1952302484 @default.
- W2590198146 hasRelatedWork W2032188922 @default.
- W2590198146 hasRelatedWork W2038274064 @default.
- W2590198146 hasRelatedWork W2134986421 @default.
- W2590198146 hasRelatedWork W2352031239 @default.
- W2590198146 hasRelatedWork W2416369235 @default.
- W2590198146 hasRelatedWork W2417717847 @default.
- W2590198146 hasRelatedWork W2503036974 @default.
- W2590198146 hasRelatedWork W2604915151 @default.
- W2590198146 hasRelatedWork W3000635299 @default.
- W2590198146 hasVolume "29" @default.
- W2590198146 isParatext "false" @default.
- W2590198146 isRetracted "false" @default.
- W2590198146 magId "2590198146" @default.
- W2590198146 workType "article" @default.